September 19, 2014 Press Release Mitsubishi Tanabe Pharma Corporation TELAVIC 250 mg Tablets, Antiviral Approval of Additional indication for Chronic Hepatitis C Genotype 2

First Page		Document Content
Date: 2014-09-19 05:20:51 Biology Medicine Pyrazines Telaprevir Cytokines Hepatitis Hepatitis C virus Interferon Hepatitis C Antivirals Pharmacology Protease inhibitors		September 19, 2014 Press Release Mitsubishi Tanabe Pharma Corporation TELAVIC 250 mg Tablets, Antiviral Approval of Additional indication for Chronic Hepatitis C Genotype 2 Add to Reading List Source URL: www.mt-pharma.co.jp Download Document from Source Website File Size: 18,19 KB Share Document on Facebook

	Treatment of Chronic Hepatitis C - January 2016 Update (The changes compared to the November 2015 Update are highlighted in yellow) Swiss Association for the Study of the Liver and Swiss Society for Infectious Diseases DocID: 1qOAQ - View Document
	NIH Public Access Author Manuscript Haemophilia. Author manuscript; available in PMC 2015 September 01. NIH-PA Author Manuscript DocID: 1qx0K - View Document
	Treatment of Chronic Hepatitis C - January 2016 Update (The changes compared to the November 2015 Update are highlighted in yellow) Swiss Association for the Study of the Liver and Swiss Society for Infectious Diseases DocID: 1qfUf - View Document
	Transplantologiya – 2015. – № 1. – P. 13–22. The use of telaprevir for the treatment of hepatitis C in patients undergoing liver transplantation (Literature review and clinical experience) M.Sh. Khubutiya1, V.E DocID: 1ngSx - View Document
	Microsoft PowerPoint - PHT SLA Spring 2012_ClinicalTrials_WEB.pptx DocID: 1msHW - View Document